Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 11 (2), 105-111

Presence of Fluorescent in Situ Hybridization Abnormalities Is Associated With Plasma Cell Burden in Light Chain Amyloidosis

Affiliations
Clinical Trial

Presence of Fluorescent in Situ Hybridization Abnormalities Is Associated With Plasma Cell Burden in Light Chain Amyloidosis

Lindsay Hammons et al. Hematol Oncol Stem Cell Ther.

Abstract

Objective/background: To assess abnormalities found on CD138-enriched fluorescent in situ hybridization (FISH) studies on pre-treatment bone marrow in systemic amyloid light-chain amyloidosis (AL) and correlate findings between these abnormalities with organ involvement and 1-year survival.

Methods: We reviewed 107 patients with systemic AL to identify the impact of a diagnostic FISH study done on plasma cell-enriched bone marrow in our institution between January 2010 and January 2015; 77 had pre-treatment testing performed.

Results: A total of 77 (61%) patients had abnormal FISH including: hyperdiploidy (29%), t(11;14), (20%), hypodiploidy (16%), t(4;14), (1%), del17p (5%), and+1q21 (5%). Abnormal FISH studies were more likely in those patients with plasma cell involvement≥10% (p=.002). FISH abnormalities were not shown to correlate with stage, cardiac involvement, or survival at 1year. One-year survival was significantly affected by stage at diagnosis and presence of cardiac and hepatic amyloid involvement.

Conclusion: We conclude that in AL, FISH abnormalities are associated with clonal burden. We found no impact of these markers on the type of organ involvement or 1-year survival.

Keywords: Amyloid; Fluorescent in situ hybridization; Light-chain amyloidosis; Myeloma.

Similar articles

See all similar articles

Cited by 1 article

Publication types

LinkOut - more resources

Feedback